Login to your account

Username *
Password *


0757 0467130


Your shopping cart is empty!
Your quote cart is empty!

 Clarius Mobile Health, a digital healthcare company, is demonstrating wireless, handheld ultrasound scanners with a mobile application for iOS and Android smart devices at the Radiological Society of North America (RSNA) meeting being held at McCormick Place, November 27-30, 2016. Clarius will be exhibiting in the North Hall, booth 6559.


Kevin Irish, MD, an interventional radiologist who has been using Clarius in test situations during the development process, said: "The ability to put ultrasound literally in the palm of your hand is an important advancement in the development of ultrasound. There are no cables, no need to find a plug, no need to have a large room to allow for bulky equipment. I can literally walk into a room with the patient and can begin scanning. Clarius will be ideal for pain management and limited interventional procedures such as line placements, thoracenteses, paracenteses and biopsies."

Wireless and compatible with most iOS and Android smartphones and tablets available today, Clarius ultrasound scanners are intended for physicians to use for quick scans at the bedside. The Clarius C3 multipurpose ultrasound scanner is designed to image the abdomen and lungs; it also incorporates a virtual phased array for quick scans of the heart.  The Clarius L7 is ideal for guiding procedures and imaging superficial structures.

"By focusing on exceptional image quality, we have succeeded in producing a handheld ultrasound scanner that appeals to a broad spectrum of physicians," said Laurent Pelissier, Chairman and CEO of Clarius Mobile Health.  "We look forward to demonstrating the unique capabilities of Clarius Scanners to the radiology community."

Clarius Scanners are water resistant for easy cleaning and sterilization.  They are powered by a rechargeable battery that is easily exchanged when running low. Built with a magnesium case, Clarius Scanners are designed to withstand challenging environments.  The company has filed for regulatory clearance in various regions.

Watch this video to learn more: https://youtu.be/zVul3CWtpkI


Founded by ultrasound innovators, Clarius Mobile Health aims to make ultrasound available to all clinicians. Our affordable handheld ultrasound scanners offer clinicians the freedom to use ultrasound anywhere they need it.  Clarius is ISO certified and is pending regulatory clearance. For more information, visit www.clarius.me.

Study finds 57% relative increase in breast cancer detection in women with dense breast tissue when Automated Breast Ultrasound (ABUS) was used together with mammography.


Chalfont St. Giles, UK – September 22, 2016 – The Automated Breast Ultrasound (ABUS) system is found to have significantly improved cancer detection in women with dense breast tissue when used together with mammography. 

The European Asymptomatic Screening Study aimed to evaluate the impact of ABUS in conjunction with full field digital screening mammography (FFDSM) in 1,668 women aged 40-74 with dense breasts. The study showed a 57 percent relative increase in breast cancer detection in dense breast tissue, or 6.6 cancers detected per 1000 women screened, compared with 4.2 cancers per 1000 women for mammography alone.[1]

“If ABUS would be a part of national screening programs in dense breasts, more cancers could be detected at an earlier stage. Many countries are working to try to optimise screening so that each woman can get examinations according to her assessed risk,” said Dr Brigitte Wilczek, lead researcher on the ABUS study.

Dense breast tissue is linked with an increase in the risk of developing cancer. It also makes detecting cancer more difficult. This is because both masses and breast tissue appear white in the mammogram, which makes the search for masses like a search for a snowball in a snowstorm. By contrast, masses appear dark against white tissue with ultrasound technology. 

Dense breasts are particularly common in younger women and seems to reduce with age, as on average 74% of women in their 40s, 57% of women in their 50s, 44% of women in their 60s and 36% of women in their 70s have dense breast tissue.[2]

In the study, recently published in the European Journal of Radiology, the FFDSM was first used in the examination followed by a 3D ABUS exam which took 15 minutes to complete per patient. The inclusion criteria for the women in the study was that they be 40 years or older, asymptomatic, and have heterogeneously dense parenchyma or extremely dense breast on assessment by the radiographer in the screening.

“The study shows that it is feasible to implement 3D ABUS into a high volume mammography center and increase the cancer detection rate while maintaining an acceptable low recall rate,” said Dr Wilczek.

The recall rate for ABUS and FFDSM combined was only +0.9% compared to FFDSM alone. This is an acceptable low recall rate well within the recommendations of the European guidelines for quality assurance in breast cancer screening.[3]

The new generation of Automated Breast Ultrasound, the InveniaTM ABUS, will be presented at the European Society of Breast Imaging in Paris, September 23-24, 2016.

About GE Healthcare:

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world.  GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.  




Sponsored by International Ultrasound Services Lt

New Hybrid System Combines Significant Advanced Applications with Next Generation ZONE Sonography® Technology

Mountain View, CA – November 22, 2016 – Shenzhen Mindray Bio-Medical Electronics Co.,Ltd. (Mindray), a leading global developer, manufacturer and marketer of medical devices, is introducing its new Resona 7 premium ultrasound system at the annual Radiology Society of North America (RSNA) congress being held in Chicago, IL November 27 – December 2, 2016. Integrating ZONARE’s revolutionary ZONE Sonography Technology (ZST) with Mindray’s rich repertoire of workflow and user interface advances, the Resona 7 offers premium imaging capabilities with a substantial family of features.

“The Resona 7 system is the result of leveraging Mindray and ZONARE technologies,” said Glen McLaughlin, PhD, president of Mindray/ZONARE and chief product officer, Ultrasound for Mindray. “This powerful combination provides the clinician superb imaging, user interface and workflow solutions. The ergonomics were designed with input from our customers to optimize comfort and maximize patient throughput.”

The system provides crystal clear B-mode imaging capabilities with unrivaled detail resolution and image uniformity across all radiology applications. Ultrasensitive Doppler modes and high-speed digital signal processing are designed to display hemodynamic states from the skin line to depths of up to 40 centimeters without compromising frame rate. An intuitive, customizable gesture-powered touch screen enables logical and efficient workflow and an enhanced user experience.

Designed by users for users, the Resona 7 features a fully customizable multi-gesture touch screen tailored to user needs and workflow. Features include six-way adjustable control panel with electronic height adjustment, a 12.1 inch tilting multi-touch screen and an electronic floating control panel, which moves left/right, up/down and back/forth.

“Coupling premium imaging with advanced workflow features and user-directed ergonomic design, the Resona 7 moves premium level ultrasound imaging into the next generation,” McLaughlin said. “We will continue to expand our core technologies working closely with our valued clinicians and users in support of our mutual goals of providing excellence in patient care.”

About Mindray/ZONARE

Mindray is a leading developer, manufacturer and marketer of medical devices worldwide. Mindray maintains its global headquarters in Shenzhen, China; North American headquarters in Mahwah, New Jersey; and multiple development facilities and offices in major international markets including an ultrasound Innovation Center in Silicon Valley, CA. Mindray supplies a broad range of products across three primary business segments, patient monitoring and life support, in-vitro diagnostics, and medical imaging systems.

ZONARE is a wholly owned subsidiary of Mindray located in Silicon Valley, CA. As a Mindray Center of Innovation, the company is solely dedicated to ultrasound excellence through its innovative, award-winning next generation technology which provides the platform for the company’s Living Technology designed to meet its customers evolving imaging needs. The patented design and ZONE Sonography Technology (ZST) architecture of the Z.One PRO and ZS3 platforms deliver high-end image quality and clinical versatility.


sponsored by iuslondon.co.uk

Contact Us

hideCall: 0757 0467130

   or    07860 637522